Incidental Variants Are Critical for Genomics  by Biesecker, Leslie G.
COMMENTARY
Incidental Variants Are Critical for Genomics
Leslie G. Biesecker1,*
The topic of incidental variants detected through exome and genome sequencing is controversial, both in clinical practice and in
research. The arguments for and against the deliberate analysis and return of incidental variants focus on issues of clinical validity,
clinical utility, autonomy, clinical and research infrastructure and costs, and, in the research arena, therapeutic misconception. These
topics are briefly reviewed and an argument is made that these variants are the future of genomic medicine. As a field, we should
take full advantage of all opportunities to study these variants by searching them out, returning them to patients and research
participants, and studying their utility for predictive medicine.This essay provides a rationale for
aggressively pursuing both the
research and clinical utilization of
incidental genomic findings, because
these variants are the future of clinical
genomics. I make this plea for a host
of reasons, recognizing the many
challenges, arguing nonetheless that
seizing this opportunity is essential
for the progress of the field of research
in clinical genomics, justifiable as
proper medical care in the clinical
context and necessary to maintain
public support of the scientific enter-
prise. It is a challenge to the claim
that such variants are ‘‘a threat to
genomic medicine’’1.
Moving forward with incidental
variants means that as researchers
and as clinicians, we shouldmaximize
our opportunities to identify sec-
ondary variants, both in the research
and in the clinical arenas. In the clin-
ical arena, we should return those
variants to patients when they meet
reasonable standards for proof of cau-
sality and can significantly improve
the medical care of our patients. In
the research arena, we should study
incidental variants to learn what they
can tell us about the full spectrum of
genotypes and phenotypes. Because
this research improves our knowledge
of incidental variants, they can be
moved onto, or perhaps in some cases
off of, the lists of genes and variants
known to be medically useful.
At the same time, it is important
to acknowledge the limitations and1National Human Genome Research Institute, Natio
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both the clinical and research realms.
These issues have led some to suggest
that we should avoid acquiring or
redact incidental variants from exome
and genome results, withhold the var-
iants that we do find from research
subjects, or not include reporting of
such variants from clinically indicated
genome and exome testing results. A
key limitation regarding incidental
variants is that our ability to interpret
these variants is inadequate.1–5 Specif-
ically, we do not have adequate data
on the full spectrum of genotype-
phenotype correlations6 and we
cannot interpret the overwhelming
majority of such variants. A second
important issue is that, in the research
realm, the analysis and return of such
variants can blur the distinction of the
roles of researcher versus clinician and
increase the risk of therapeutic
misconception.7–9 A third limitation
is logistic: in neither the research nor
clinical domains do we have adequate
infrastructure—physical (e.g., infor-
matics), procedural (e.g., informed
IRBs and consent processes),10–14
or human (e.g., researchers able
to identify variants and clinicians
able and willing to act on such
results)4,15–17—to analyze and use
incidental variants to improve the
medical care of research participants
or patients. These limitations and
concerns are real and valid but repre-
sent only the ‘‘glass half empty’’ side
of the equation.nal Institutes of Health, Bethesda, MD 20892, USA
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Notwithstanding all of the challenges
described above, incidental variants
with important health implications
can be identified18–20 and consensus
on the propriety of returning results
is attainable for carefully delimited
sets of genes and variants.21,22 Also,
the American College of Medical
Genetics has recently recommended
return of specific types of incidental
variants for 57 genes and 24 condi-
tions,23 although there is much
debate and concern about this recom-
mendation. It is also clear that in spite
of the important ethical concerns that
have been raised, the ethical con-
sensus is shifting toward returning
incidental findings.22,24–27 In addi-
tion, there is a social-political issue
to address. Most genomic scientists
depend entirely or primarily on the
generosity and support of the public
through their funding of research.
There is also the altruism and generos-
ity of the research participants28,29,
and the general public has high
expectations of what they want
researchers to do on behalf of partici-
pants.30,31 The views and desires of
research participants drive the effort
to translate basic genomics into clin-
ical genomics—we cannot continue
to promise that the health benefits
of the Genome Project32 are forever
around the next corner. Incidental
variants, beyond the primary variants
we seek in clinical care and research,rights reserved.
Box 1. A Case Study in the Value of Returning Incidental Findings
A 47-year-old man was enrolled in the ClinSeq study because of a personal and family history of early onset
myocardial infarction in the absence of hyperlipidemia. Whole-genome sequencing was performed to identify
the cause of this disorder, which, to date, has not been successful. During a general review of his whole-genome
sequence data, it was apparent that the average read-depth coverage of a segment of chromosome 17pwas reduced
by about 50%. This region corresponded to the classical deletion seen inpatientswithhereditarynerve andpressure
palsies (HNPP;MIM162500), and the deletionwas confirmed by CLIA-validated testing. The result was returned to
theparticipantwithmedical andgenetic counseling,whereupon itwas learned thathehadbeenmisdiagnosedwith
herniated lumbar discs with radiculopathy and had been recommended to undergo surgery for this diagnosis. The
surgerywas declined and the patient has undergone physical andoccupational therapy forHNPPwith good results.are an important additional opportu-
nity to improve health (Box 1). The
public and the body politic are likely
to react negatively to the scientific
enterprise if subjects are harmed by
policies that preclude or discourage
the return of incidental findings on
the basis that it is too expensive, too
difficult, too time consuming, re-
quires too much paperwork, or is not
legally obligatory to identify and re-
turn results to research participants
with life-threatening predispositions
to diseases.1,3,33–36 We cannot simul-
taneously argue that genomics can
deliver major health advances and at
the same time ignore incidental muta-
tions for severe diseases in the partici-
pants that we study. I predict that
ignoring such variants would lead to
a serious backlash in public opinion
regarding genomic research, with
major repercussions for the field.
If the glass is indeed half full, we
must find a way forward toward an
approach to healthcare that is based
as much on prevention and prophy-
laxis as it is on symptomatic diagnosis
and treatment and overcome the
limitations and challenges described
above. One approach would be to
organize large, new cohorts of healthy
patients to perform prospective
studies to explore the ability to predict
and avert disease. Regrettably, the
United States is somewhat behind in
these endeavors as compared to other
countries such as Canada and the
European Union. A major impedi-
ment to such studies is the enormous
costs of organizing such studies and
the long timelines necessary for
recruitment, as well as data generationand subsequent analysis. A second,
less expensive, and faster way forward
may be to leverage currently funded
clinical genomics research studies
(and perhaps clinical genomic testing
as well) to pilot approaches for predic-
tive medicine. Investigators have
described thousands of individuals
who are being sequenced for a myriad
of indications; intellectual disability,
malformations, cancer, heart disease,
undiagnosed diseases, etc. Although
we celebrate the successes of many of
these endeavors to understand the
genetic basis of these disorders, some-
thing is being missed. These exome
and genome studies are rightly
focused on the primary disease that
led to the sequencing, but the
sequence data from all of these studies
could provide a nearly free set of
genomic data upon which predictive
medicine exploratory research could
be performed. For every child with
intellectual disability enrolled in a
trio sequencing study, there are four
parental alleles that may harbor a
mutation in a gene associated with
cancer susceptibility,20 cardiomyop-
athy, malignant hyperthermia, or
other potentially occult and serious
medical disorders. For every thousand
such trios, there are likely to be dozens
of individuals with a rare, apparently
pathogenic variant in a gene that
predisposes them to the future devel-
opment of a significant medical
condition. I suggest that research par-
ticipants with incidental variants in
these studies should be aggregated
and studied for that secondary disor-
der as a part of the primary protocol,
or they should be enrolled in an inci-The American Journal of Humadental variants protocol where the
penetrance, clinical utility of report-
ing of the variant, and long-term
outcome could be assessed and fol-
lowed. It would be critical to design
such studies in a manner that allowed
integration of data across the multiple
genes and disorders to test the
hypothesis that the detection of a set
of such variants improved the overall
health and well-being of these inci-
dental cohorts. The power of geno-
mics is that it provides a broad view
of the landscape of heritability – it is
wasteful to discard variants in all genes
other than the primary causative
variant.
In spite of the challenges and
expenses of addressing incidental var-
iants, I believe that they provide us
with an opportunity to build the
foundation of preventive, individual-
ized medicine.37 I also believe that
research participants, the public, and
their elected representatives (our fun-
ders) expect us to do this and that
ongoing support of clinical genomics
is dependent upon us taking up this
challenge and moving forward.
When a field is faced with a daunting
challenge, there are always a myriad
of reasons not to go forward, and
there will always be skeptics. But we
should not ignore the challenge of
incidental findings and risk missing
the opportunity of all that they will
teach us; the time is now.
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